Identification of first biomarker for major depression could enable better diagnosis and treatment

Wellcome Trust's picture
Printer-friendly versionPrinter-friendly versionPDF versionPDF version

18 February 2014

Depression biomarker sm

Teenage boys who show a combination of depressive symptoms and elevated levels of the ‘stress hormone’ cortisol are up to 14 times more likely to develop major depression than those who show neither trait, according to research funded by the Wellcome Trust.

In a study published today in the 'Proceedings of the National Academies of Science', researchers from the University of Cambridge have identified the first biomarker - a biological signpost - for major depression. They argue that this could help identify those boys who are at greatest risk of developing the illness and provide treatment at an earlier stage.

Major (clinical) depression is a debilitating mental health problem that will affect one in six people at some point in their lives. However, until now there have been no biomarkers for it; this is believed to be, in part, because both the causes and the symptoms can be so varied.

“Depression is a terrible illness that will affect as many as ten million people in the UK at some point in their lives,” says Professor Ian Goodyer from the University of Cambridge, who led the study. “Through our research, we now have a very real way of identifying those teenage boys most likely to develop clinical depression. This will help us strategically target preventions and interventions at these individuals and hopefully help reduce their risk of serious episodes of depression and their consequences in adult life.”

Dr Matthew Owens from the University of Cambridge, first author on the study, adds: “This new biomarker suggests that we may be able to offer a more personalised approach to tackling boys at risk for depression. This could be a much-needed way of reducing the number of people suffering from depression, and in particular stemming a risk at a time when there has been an increasing rate of suicide amongst teenage boys and young men.”

The researchers measured levels of cortisol in saliva from two separate large cohorts of teenagers. The first cohort consisted of 660 teenagers, who provided four early-morning samples on schooldays within a week and then again 12 months later. The researchers were able to show within this cohort that cortisol levels were stable over one year in the population at large in both boys and girls.

A second cohort, consisting of 1198 teenagers, provided early morning samples over three school days.

Using self-reports about current symptoms of depression collected longitudinally over the 12 months and combining these with the cortisol findings, Professor Goodyer and colleagues were able to divide the teenagers in the first cohort into four distinct groups, ranging from those with normal levels of morning cortisol and low symptoms of depression over time (group 1) through to those teenagers with elevated levels of morning cortisol and high symptoms of depression over time (group 4) - this latter group made up one in six (17%) of all subjects. Importantly, the research group replicated exactly these four groups using the second cohort.

Because the two cohorts gave identical results, Professor Goodyer and colleagues were able to combine them and study the whole sample of 1858 teenagers for the probability of developing clinical major depression and other psychiatric disorders when followed up 12 to 36 months later.

The teenagers in group 4 were on average seven times more likely than those in group 1, and two to three times more likely than in the other two groups, to develop clinical depression. Further analysis revealed that boys in group 4 were 14 times more likely to suffer from major depression than those in group 1 and two to four times more likely to develop the condition than either of the other two groups. Girls in group 4, on the other hand, were only four times more likely than those in group 1 to develop major depression, but were no more likely to develop the condition than those with either elevated morning cortisol or symptoms of depression alone. The findings suggest gender differences in how depression develops.

In order to demonstrate that the combination of high levels of cortisol and depressive symptoms was indeed a biomarker for a particular type of depression, the researchers needed to show that the teenagers in group 4 were different from those in the other groups. They demonstrated this using a memory test completed on the first cohort consisting of systematically recording episodes recollected from an individual's life (known as ‘autobiographical memory’) under standardised test conditions.

Both boys and girls in group 4 were particularly poor at systematically recollecting specific autobiographical memories from over 30 example situations across different social and personal domains. For example, when given the word ‘picnic’, most teenagers give a fairly detailed account of a time when they went on a picnic and who they were with; in group 4, individuals tended to give very little, and more general non-specific, information. This supports evidence from the scientific literature that suggests that high cortisol acts to suppress autobiographical memory recall.

The researchers hope that having an easily measurable biomarker - in this case, elevated cortisol plus depressive symptoms - will enable primary care services to identify boys at high risk and consider new public mental health strategies for this subgroup in the community.

The research has been welcomed by the Wellcome Trust, which funded the study. Dr John Williams, Head of Neuroscience and Mental Health at the Trust, says: “Progress in identifying biological markers for depression has been frustratingly slow, but now we finally have a biomarker for clinical depression. The approach taken by Professor Goodyer’s team may yet yield further biomarkers. It also gives tantalising clues about the gender differences in the causes and onset of depression.”
 

Image: Depression. Credit: Adrian Cousins/Wellcome Images

 
Contact
 
Meera Senthilingam
Senior Media Officer
Wellcome Trust
+44 (0)20 7611 7262
 
Craig Brierley
Media Relations Manager
Wellcome Trust
+44 (0)20 7611 7329
M +44 (0)7957 468218
 
Notes for editors
 
Reference
Owens M et al. Elevated morning cortisol is a stratified population level biomarker for major depression in boys only with high depressive symptoms. PNAS; e-pub 17 Feb 2014.
 
About the Wellcome Trust
The Wellcome Trust is a global charitable foundation dedicated to achieving extraordinary improvements in human and animal health. It supports the brightest minds in biomedical research and the medical humanities. The Trust’s breadth of support includes public engagement, education and the application of research to improve health. It is independent of both political and commercial interests.

News Source : Identification of first biomarker for major depression could enable better diagnosis and treatment

Copy this html code to your website/blog to embed this press release.